Reglagene

Executive Summary

Reglagene is a private therapeutics company based in San Diego, specializing in the design and development of brain-penetrant medicines for the safe and effective treatment of brain diseases. Founded in 2018, the company operates at the intersection of oncology and genetics & genomics, reflecting its focus on CNS-related conditions, including brain cancers and genetic disorders affecting the brain. Despite its stage being listed as 'Approved,' no specific approved products or FDA counts are publicly available, suggesting either a recent approval or a status that may refer to a different milestone. Reglagene leverages its expertise in blood-brain barrier penetration to create targeted therapies that address high unmet needs in neurological and oncological indications. The company remains private with no disclosed total funding or valuation, and its pipeline details are not publicly enumerated, limiting visibility into specific programs. However, its core technology platform for brain-penetrant drug design positions it as a potential player in the CNS therapeutics space, where effective drug delivery to the brain remains a major challenge.